The North America Large And Small-scale Bioprocessing Market would witness market growth of 13.4% CAGR during the forecast period (2023-2030).
Large-scale bioprocessing continues to be driven primarily by the production of biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies. This trend is likely to persist as the demand for biologics remains high. The adoption of single-use bioprocessing technologies is increasing in large-scale bioprocessing. Single-use systems offer flexibility, reduce the risk of cross-contamination, and lower operational costs compared to traditional stainless-steel systems. There is a growing interest in continuous bioprocessing as it provides improved process control, reduced production costs, and faster time-to-market.
Miniaturization of bioprocessing equipment and the use of microfluidic devices are gaining traction in small-scale bioprocessing. These technologies enable rapid prototyping and experimentation. Small-scale bioprocessing is essential for developing and manufacturing cell and gene therapies, which have grown tremendously in recent years. Small-scale bioprocessing is particularly suited for customized and personalized medicine approaches, allowing for tailored treatments based on individual patient needs. Small-scale bioprocessing is widely used in academic and research labs for bioprocess development and optimization, and this trend is expected to continue.
North America is a thriving hub for the market, with a diverse and dynamic ecosystem encompassing pharmaceutical giants, biotech startups, academic research, and contract service providers. This diversity and innovation continue to drive advancements in bioprocessing technologies and contribute to the growth of the biopharmaceutical industry in the region. Due to these aspects, the market will grow in upcoming years.
The US market dominated the North America Large And Small-scale Bioprocessing Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $39,322.4 million by 2030. The Canada market is registering a CAGR of 16% during (2023 - 2030). Additionally, The Mexico market would showcase a CAGR of 15% during (2023 - 2030).
Based on Scale, the market is segmented into Industrial Scale, and Small Scale. Based on Use Type, the market is segmented into Multi Use, and Single Use. Based on Mode, the market is segmented into In-house, and Outsourced. Based on Application, the market is segmented into Biopharmaceuticals, Speciality Industrial Chemicals, and Environmental Aids. Based on Workflow, the market is segmented into Industrial Downstream Processing, Fermentation, and Upstream Processing. Based on Product, the market is segmented into Bioreactors/Fermenters, Cell Culture Products, Filtration Assemblies, Bioreactors Accessories, Bags & Containers, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Large And Small-scale Bioprocessing Market is Predict to reach $159.6 Billion by 2030, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., GE healthcare, Corning Incorporated, Sartorius AG, Lonza Group AG (Capsugel), Meissner Filtration Products, Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd. and Eppendorf SE.
By Scale
By Use Type
By Mode
By Application
By Workflow
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
